Dioctanoylphosphatidic acid sodium (DOPA sodium) is a bioactive phosphatidic acid (PA) derivative serving as a key lipid signaling molecule. Derived from glycerophospholipids via the action of phospholipase D (PLD), it acts as a precursor to diacylglycerol (DAG) and lysophosphatidic acid (LPA). It specifically binds to and activates the FRB domain of the mammalian target of rapamycin (mTOR), thereby promoting mTOR phosphorylation. Additionally, it modulates the respiratory burst in phagocytic cells such as neutrophils. In oncological studies, it has been shown to enhance the viability of gallbladder cancer (GBC) cells inhibited by histone deacetylase inhibitors (HDACI), suggesting a protective role against epigenetic-mediated growth suppression.